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Abstract
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Resistance of bacterial pathogens to current antibiotics has grown to be an urgent crisis.
Approaches to overcome this challenge include identification of novel targets for discovery of new
antibiotics. Bacterial topoisomerase I is present in all bacterial pathogens as a potential target for
bactericidal topoisomerase poison inhibitors. Recent efforts have identified inhibitors of bacterial
topoisomerase I with antibacterial activity. Additional research on the mode of action and binding
site of these inhibitors would provide further validation of the target and establish that bacterial
topoisomerase I is druggable. Bacterial topoisomerase I is a potentially high value target for
discovery of new antibiotics. Demonstration of topoisomerase I as the cellular target of an
antibacterial compound would provide proof-of-concept validation.

Type IA topoisomerase as a novel bactericidal target
The need for new antibiotics
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The emergence of bacterial pathogens resistant to current antibiotics is an increasingly
urgent worldwide public health problem [1]. New drugs are needed for therapeutic regimens
that can be effective for treatment of multidrug-resistant and extensively drug-resistant
tuberculosis [2]. Drug-resistant gram-negative pathogens including Pseudomonas
aeruginosa [3] and Acinetobacter baumannii [4] are becoming more prevalent in the
hospital settings. Methicillin-resistant Staphylococcus aureus strains have developed
resistance to vancomycin, traditionally a drug of last resort [5]. New antibiotics that can be
effective against multiple bacterial pathogens, including the ESKAPE pathogens
(Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, P.
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aeruginosa and Enterobacter species) [6], are much needed [7]. Focusing on a novel target
different from the targets involved in mode of action of current antibiotics could provide
new drugs that might avoid the resistance mechanisms for current drugs.
Bacterial topoisomerase I as a novel bactericidal target

Author Manuscript
Author Manuscript

At least one type IA topoisomerase enzyme can be found in every bacterium [8]. This class
of topoisomerases regulates DNA topology by first generating a break on a single strand of
DNA with a tyrosine nucleophile at the active site, forming a covalent complex with the
cleaved DNA via a 5′-phosphotyrosine linkage [9]. The DNA is rejoined after the movement
of DNA strands necessary for the DNA topological change. The type IA topoisomerase
function is essential for resolving topological barriers that require single-strand DNA
passage [10]. Type IIA topoisomerases, in contrast, break and rejoin a double strand of DNA
[11]. Bacterial type IIA topoisomerases (gyrase and topoisomerase IV) are highly utilized
targets for antibacterial drugs, including the quinolones and other chemical compounds [12–
14]. The widely prescribed quinolones are highly effective bactericidal agents not only
because the cellular functions of the type IIA topoisomerases are inhibited by the quinolone
action but also due to the fact that stabilized ternary complex formed by gyrase or
topoisomerase IV with cleaved DNA plus the quinolone triggers chromosomal
fragmentation and bacterial cell death [12]. Inhibitors that can cause cell death by trapping
the covalent intermediate after DNA cleavage by topoisomerases are known as
topoisomerase poison inhibitors [15]. Unlike catalytic enzyme inhibitors that must inhibit
nearly all of the cellular activity to be effective, topoisomerase poison inhibitors need to trap
only a relatively small subset of the cellular topoisomerase molecules as covalent complex
to trigger cell death [16]. Numerous anticancer drugs of clinical importance have been found
to act as poison inhibitors against human type IIA topoisomerases, as well human type IB
topoisomerase [15]. An interfacial mechanism has been proposed for these topoisomerase
poison inhibitors with the inhibitors binding to both enzyme and DNA in the ternary
complex [17]. Type IA topoisomerase present in all bacterial pathogens could be a novel
target for bactericidal antibiotics. Bacteria that have more than one type IA topoisomerases,
for example, Helicobacter pylori and Escherichia coli, would provide opportunity for dual
targeting of the homologous type IA enzymes to decrease the rate of drug resistance.
Bacterial cell death from dominant lethal topoisomerase I mutations that inhibit DNA
religation

Author Manuscript

Since type IA topoisomerases covalent complex accumulation would lead to single-strand
breaks in chromosomal DNA instead of the double-strand breaks expected from
accumulation of type IIA topoisomerase covalent complexes, it needs to be verified that the
bacterial topoisomerase I covalent complex accumulation can initiate the bacterial cell death
pathway. This was accomplished following random mutagenesis of recombinant bacterial
topoisomerase I and identification of topoisomerase I mutants that can induce the SOS DNA
repair system in response to the DNA damage [18,19]. The D111N mutation at the first
aspartate of the DxD motif in the TOPRIM domain of E. coli topoisomerase I was found to
be extremely lethal as a result of loss of DNA rejoining activity due to the absence of the
negatively charged carboxylate side chain required for divalent Mg2+ binding [20]. Small
molecules that interfere with Mg2+ binding at the active site could potentially function as
Future Med Chem. Author manuscript; available in PMC 2016 January 01.
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type IA topoisomerase poison inhibitors [19]. A strictly conserved arginine residue proximal
to the active site tyrosine was also found to the critical for DNA rejoining [21].
Potential processing activities for bacterial topoisomerase covalent complexes

Author Manuscript

The bacterial topoisomerase I mutants that accumulate the covalent cleavage complex allow
genetic studies of the processing and repair pathways of the topoisomerase covalent
complex in E. coli. The initial single-strand DNA break may be converted by RuvAB and
RecG into a double-strand DNA break [22]. SOS response is thus induced to activate the
RecBCD pathway for repair of the double-strand break [23]. It is not clear which bacterial
proteolytic or nucleolytic activities might be responsible for removing the covalently bound
topoisomerase protein, but SbcCD nuclease is a likely candidate [24,25]. Nuclease
homologues of SbcCD have been shown to remove covalently bound topoisomerases from
DNA in eukaryotes [26]. TDP1 and TDP2 tyrosyl-DNA phosphodiesterases have been
shown to cleave the phosphotyrosine linkage following proteolytic processing of the
topoisomerase covalent complex in eukaryotes [15,27–28]. TDP1 and TDP2 inhibitors are
sought in screening assays for combination chemotherapy to improve response to anticancer
topoisomerase poison inhibitors [29,30]. Homologs of TDP1 and TDP2 or enzymes of
similar functions remain to be identified in bacteria.

Essential functions of bacterial type IA topoisomerase
Topoisomerase I function in stress response and virulence
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Bacterial type IA topoisomerases participate in many essential cellular processes including
replication, transcription, recombination and repair [31]. For bacteria with more than one
type IA topoisomerase encoded in the genome, it might be possible to isolate mutants
missing one of the type IA topoisomerase activities under laboratory growth conditions.
However, as illustrated by the studies of E. coli ΔtopA mutants, absence of the topA encoded
topoisomerase I function results in hypersensitivity to antibiotics as well as high temperature
and oxidative stress [32–34]. This is likely due to the requirement of topoisomerase I
relaxation activity for removal of transcription-driven supercoiling at loci with high rate of
transcription of genes needed for adaption and survival in the natural or host environments
[35]. Hypernegative supercoiling and R-loop formation during transcription elongation
would prevent synthesis of the stress response genes, resulting in loss of viability [36].
While either bacterial topoisomerase I and topoisomerase III can probably meet the
requirement of type IA topoisomerase activity in chromosome segregation [37,38], the
relatively slow rate of topoisomerase III catalytic activity for relaxation of negative
supercoils [39] would likely not meet the demands for rapid transcription elongation in the
host environment. Interestingly, even though H. pylori has two type IA topoisomerases that
are annotated as TopA because these enzymes have higher degree of sequence homology to
known bacterial topoisomerase I than topoisomerase III, results from transposon
mutagenesis experiment indicate that the longer form of the H.pylori TopA is nevertheless
essential, suggesting that these two TopA enzymes have nonoverlapping functions for H.
pylori, which may include adaptation in the acidic environment [40,41].
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Bacterial type IA topoisomerases can also have essential roles in pathogenic virulence
through the regulation of transcription and recombination. Deletion of E. coli topA gene
reduced the expression of FooB, a regulator of fimbriae F165(1) in pathogenic E. coli [42].
Inactivation of Pectobacterium atrosepticum topoisomerase IIIβ has been shown to result in
reduced virulence due to hyperexcision of the pathogenicity island HAI2 [43]. Additional
type IA topoisomerases were found encoded by the pXO1 virulence plasmid of Bacillus
anthracis [44], and cystic fibrosis associated isolates of P. aeruginosa [45].
Type IA topoisomerase function required for viability
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In organisms with only one type IA topoisomerase, the topA gene encoding topoisomerase I
is essential for viability, as demonstrated for Mycobacterium tuberculosis [46] and
Streptomyces coelicolor [47]. These topoisomerase I enzymes might be responsible for
functions associated with topoisomerase III in other bacteria that have both of these type IA
topoisomerases, including resolving intermediates in chromosome segregation and
recombination [31]. While E. coli topoisomerase III is known to interact with RecQ helicase
to control recombination [48], RecQ homologs are not found in Mycobacteria. Helicases
that may interact with Mycobacterium topoisomerase I in replication and recombination
functions remain to be identified. For consideration of another potential function for
bacterial topoisomerase I enzyme, human type IA topoisomerase IIIβ has been shown to be
an RNA topoisomerase required for regulation of mRNA metabolic reactions [49,50]. E. coli
topoisomerase III can also act as an RNA topoisomerase [51], but it remains unclear if a
bacterial RNA topoisomerase activity might be utilized to modify cellular RNA structures.

Author Manuscript

While type IA topoisomerase poison inhibitors remain a highly desirable class of inhibitors
for discovery as broad-spectrum bactericidal antibiotics leads, catalytic inhibitors of
bacterial topoisomerase I could potentially be useful for targeting organisms that absolutely
require topoisomerase I activity for viability, for example, in treatment of tuberculosis. The
requirement of topoisomerase I function in transcription during stress response further
enhances the potential of synergistic efficacy from topoisomerase I inhibitors if used along
with other antibiotics in combination antibacterial therapy. The identification of a small
molecule inhibitor with topoisomerase I as the proven mode of antibacterial action and the
required selectivity would validate bacterial topoisomerase I as a druggable target.

Assays development for high-throughput screening
Cell-based SOS induction assay

Author Manuscript

Recombinant bacterial topoisomerase I with mutations that mimic the effect of
topoisomerase poison inhibitors for accumulation of covalent complex with cleaved DNA
were initially identified based on the resulting SOS response induced in E. coli [18].
Trapping of gyrase covalent complex by quinolones was also known to induce the SOS
response in E. coli [52]. A high-throughput screening (HTS) assay aiming to identify type
IA topoisomerase poison inhibitors was therefore based on induction of the E. coli SOS
response [53]. Luciferase activity from plasmid encoded dinD1:luxCADBE fusion [54] was
utilized as reporter of SOS induction via transcription from the dinD1 promoter. Synthesis
of the recombinant luxCADBE gene products from Photorhabdus luminescens can generate
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luminescence without addition of luciferase substrate. The HTS assay attempted to identify
compounds that could induce greater luciferase signal when wild-type recombinant Yersinia
pestis topoisomerase I was over-expressed in comparison to when an active site mutant of Y.
pestis topoisomerase I was overexpressed. Three bacterial topoisomerase I poison inhibitors
were identified from HTS screening [53]. These compounds had no effect on type IB
vaccinia topoisomerase I cleavage, but two of the compounds derived from phenanthrene
and fluorene were later found to be poison inhibitors for mitochondrial type IIA
topoisomerases in Trypanosoma brucei [55]. The SOS induction assay may select for DNA
intercalators. While many topoisomerase poison inhibitors are DNA intercalators that can
act as interfacial inhibitors, DNA intercalators are also likely to have a high tendency of
affecting activities of more than one class of DNA topoisomerases.
Cell-based supercoiling-sensitive reporter assay
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Inhibition of bacterial gyrase or topoisomerase I activity in vivo is expected to alter global
chromosomal DNA supercoiling [56]. E. coli promoters for gyrA and topA gene respond
reciprocally to changes in supercoiling in the homeostatic regulation of supercoiling [57,58].
In the design of an assay for in vivo bacterial DNA supercoiling, the ratio of the specific
activity of ptopA to the specific activity of pgyrA monitored by luciferase reporter plasmids
was defined as quotient of supercoiling (Qsc) [59]. The Qsc value increases in the presence
of topA mutation and decreases in the presence of gyrase mutation or catalytic inhibitors of
gyrase such as novobiocin. Plant extracts prepared from Angelica archangelica and Ruta
graveolens were found to decrease the Qsc value [59]. Decrease in Qsc was also observed in
the presence of two coumarin compounds present in these plant extracts. Compounds or
natural product extracts that increase the Qsc values as expected from inhibition of
topoisomerase I activity were not discussed. This in vivo assay could potentially be used to
identify compounds that can inhibit either the supercoiling activity of gyrase or the
relaxation activity of topoisomerase I in bacterial cells.
Topoisomerase catalytic assays based on supercoiling-sensitive DNA structures

Author Manuscript

Assays that are based on increased efficiency of intermolecular triplex formation for
negatively supercoiled DNA have been designed for identification of inhibitors of either the
supercoiling activity of DNA gyrase, or relaxation activity of topoisomerases [60,61]. These
assays can be applied in HTS of inhibitors of bacterial topoisomerase I enzymes. Maxwell et
al. developed assays based on capture of a plasmid containing triplex-forming sequence by
an oligonucleotide immobilized on microtiter plate well surface, and subsequent detection of
the plasmid captured by triplex formation with fluorescence dye [61,62]. A homogeneous
assay based on the same principle but does not require immobilization, filtration or washing
steps measured the fluorescence anisotropy of oligonucleotide labeled with fluorescent dye
following intermolecular triplex formation with plasmid [60]. This homogeneous assay has
been shown to be applicable for measuring the relaxation activity of E. coli topoisomerase I.
However, results of HTS utilizing such triplex-based assays on bacterial topoisomerase I
have not been reported.
Cruciform extrusion from inverted repeat sequence in plasmids is also dependent on
negative supercoiling [63]. This dependence on negative supercoiling was utilized to
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develop a high-throughput real-time fluorescence-based assay for detection of inhibitors of
the supercoiling activity of bacterial DNA gyrase [64]. In principle, this assay could also be
adapted to monitor the removal of negative supercoils by bacterial topoisomerase I, but such
data have not been reported for this catalytic assay.
Enzyme-based assay for increase in DNA cleavage

Author Manuscript

The assays based on triplex formation and cruciform extrusion cannot identify specifically
topoisomerase poison inhibitors. Previous studies on quinolones showed that these type II
topoisomerase poison inhibitors can inhibit bacterial cell growth at concentrations
significantly lower than the IC50 concentrations for inhibition of the overall supercoiling
catalytic activity [65] because initiation of bactericidal pathway by stabilized topoisomerase
cleavage complex on the chromosome does not require that most of the cellular
topoisomerase activity be inhibited. Nalidixic acid, the first known quinolone poison
inhibitor of E. coli gyrase, requires concentration of 100 μM or more for 50% inhibition of
the gyrase supercoiling activity [65,66]. Inhibitors with such high IC50 values would most
likely not be selected as hits to be followed up in HTS. Therefore, potential topoisomerase
poison inhibitors might not be captured with the HTS assays based on overall catalytic
activity. It is thus desirable to have a HTS assay that can detect inhibition of DNA rejoining
by bacterial topoisomerase I to identify poison inhibitors that shift the DNA cleavage–
religation equilibrium toward DNA cleavage.

Author Manuscript
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A fluorescence-based assay has been developed to detect increase in DNA cleavage
products from bacterial topoisomerase I. This assay utilizes a single-stranded
oligonucleotide that forms a stem-loop structure with a preferred cleavage site for bacterial
topoisomerase I in the single-stranded loop region indicated by an arrow (Figure 1).
Fluorescence signal from a fluorophore placed at the 5′-end is limited by a quencher present
at the 3′-end. Upon heating, fluorescence signal increases from melting of the secondary
structure. Destabilization of the structure from increase in DNA cleavage by bacterial
topoisomerase I would lead to a higher fluorescence signal. This was demonstrated with the
greater than fivefold increase in fluorescence from the G116S mutation in E. coli
topoisomerase I known to lead to deficiency in DNA religation [18,67]. The oligonucleotide
for the HTS assay was initially designed for Y. pestis topoisomerase I for identifying
inhibitors that might be useful in countering Y. pestis as a bioterror threat. E. coli and Y.
pestis topoisomerase I are nearly identical in enzymatic properties, including preference in
DNA cleavage site selection. Following assay development using the NCI Diversity Set I for
identifying suitable positive control, it was found that compound NSC28086 at 0.25 mM
concentration can result in greater than fivefold increase in fluorescence signal over
background signal in the presence of DMSO. Z′ factor of 0.7–0.8 can be achieved on
different days during pilot screening at the NERCE/NSRB screening center [67].
Counterscreening in the absence of enzyme was carried out to eliminate compounds that due
to either autofluorescence or effect on DNA structure, could result in the same degree of
fluorescence increase with or without enzyme present. The use of a fluorophore reporter
with emission in the higher wavelength range such as CAL Fluor Red 610 minimizes the
overlap of fluorescence emission wavelengths between the assay reporter and most library
compounds. There was fluorescence increase from adding NSC20806 to the oligonucleotide
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substrate alone but 25% greater increase in fluorescence could be observed in the presence
of enzyme. This HTS assay was carried out at Broad Institute. From 356,421 compounds
screened in the primary assay, 229 active compounds were identified [68].

Newly identified bacterial topoisomerase I inhibitors
A number of bacterial topoisomerase I inhibitors have been described in an earlier review
[19]. Bacterial topoisomerase I inhibitors reported in publications since then will be
discussed here. Available data on these inhibitors are summarized in Table 1.
Phenanthrene compounds

Author Manuscript
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A phenanthrene compound stephenanthrine was among the bacterial topoisomerase I poison
inhibitors identified in the HTS based on induction of SOS response in E. coli [53]. More
recently, following semi-synthesis and evaluation of alkaloids from bolden, two
phenanthrenes seconeolitsine and N-methyl-seconeolitsine (Compounds 1, 2 in Figure 2)
were found to inhibit Streptococcus pneumoniae topoisomerase I relaxation and cell growth
at concentrations of approximately 17 μM [69]. Hypernegative supercoiling of plasmid
DNA extracted from S. pneumoniae following treatment with seconeolitsine is consistent
with inhibition of cellular topoisomerase I relaxation activity by the compound. Attempts to
isolate mutants resistant to these inhibitors were not successful but overproduction of
recombinant S. pneumoniae topoisomerase I was observed to provide some degree of
protection against growth inhibition by seconeolitsine in support of topoisomerase I being an
in vivo target [69]. These phenanthrenes are DNA intercalators but their inhibition effect on
the S. pneumoniae topoisomerase I relaxation activity is distinct from the intercalator effect
of ethidium bromide, which did not appear to inhibit the bacterial topoisomerase I relaxation
activity. Inhibition of topoisomerase I relaxation activity by these phenanthrenes was
enhanced by preincubation of the inhibitors with enzyme prior to addition of DNA. It was
proposed from docking studies using a molecular model of S. pneumoniae topoisomerase I
structure that the inhibitors may be occupying the nucleotide-binding site of the enzyme
through cation–π interactions to prevent subsequent DNA substrate binding. This proposed
mechanism remains to be validated by x-ray-based structures of the enzyme–inhibitor
complex. Toxicological studies suggested that seconeolitsine and N-methyl-seconeolitsine at
30 μM did not affect human neutrophil viability [69]. N-methyl-seconeolitsine has been used
in a later study to trigger increased level of DNA supercoiling and activation of iron
transport gene fatD transcription in S. pneumoniae demonstrating the potential utility of this
compound as a probe for type IA topoisomerase function [75].

Author Manuscript

Bisbenzimidazoles
Fluorescent stains Hoechst 33342 (Compound 3, Figure 3) and Hoechst 33258 (Compound
4, Figure 3) are DNA minor groove binders that have been known to act as mammalian
DNA topoisomerase I poison inhibitors [76]. New bisbenzimidazole analogues of these
Hoechst dyes that can selectively target bacterial DNA topoisomerase I over human
topoisomerases have been synthesized and characterized [70–73]. 3,4-Dimethoxyphenyl
bisbenzimidazole [70,71] (DMA, Compound 5 in Figure 3) as well as DPA 153 [72] with a
terminal alkyne substitution (Compound 6 in Figure 3) represent independently discovered
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bisbenzimidazole analogues that inhibit E. coli topoisomerase I much more strongly than E.
coli DNA gyrase, human topoisomerase I and human topoisomerase IIα. The IC50 for E. coli
topoisomerase I inhibition by DMA was found to be 3.8 μM [70], very similar to the IC50
value of 2.5 μM for DPA 153 [72]. There was evidence that DMA can act as a poison
inhibitor for E. coli topoisomerase I, increasing the level of DNA cleavage products [70].
DMA was effective for growth inhibition of clinical isolates of E. coli, with no apparent
cytotoxic effect on mammalian cells [70,71]. The antibacterial activity of DMA increased
slightly when E. coli topoisomerase I is overexpressed, consistent with cell killing initiated
by trapping of the topoisomerase I covalent complex [70]. Additional bisbenzimidazoles
analogues have been synthesized more recently for biological assays [73]. Bisbenzimidazole
12b, 5-(4-Propylpiperazin-1-yl)-2-[2′-(4-ethoxyphenyl)-5′-benzimidazolyl]benzimidazole
(Compound 7 in Figure 3) has improved IC50 value (2 μM) over DMA and the lowest MIC
values (0.1–8 μg/ml) among the latest analogues when tested against different E. coli strains,
including drug-resistant clinical isolates and water-borne E. coli strains. Direct interaction of
this compound with E. coli topoisomerase I can be demonstrated by isothermal titration
calorimetry, with Ka value of 6.8 × 106 M−1 and ΔG value of −10.84 kcal/ml [73].
Furthermore, in vivo efficacy was demonstrated with mouse systemic infection model and
neutropenic thigh model.
Natural products as dual inhibitors of type IA & type IIA topoisomerases
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A number of natural product extracts were included in the pilot screening carried out at
NERCE/NSRB screening center with the fluorescence-based assay for bacterial
topoisomerase I poison inhibitors targeting Y. pestis topoisomerase I [67]. Lichen
Hypotrachyna sp. extract was among the natural product extracts found to result in >60%
increase in fluorescence signal versus the DMSO negative control. The extract also had
antibacterial activity against E. coli strain BAS3023 with imp4213 mutation that increases
permeability for small molecules [77]. Fractionation of the lichen Hypotrachyna sp.
(Lecanorales, Parmeliaceae) from Costa Rica resulted in identification of the depside anziaic
acid (Compound 8 in Figure 4) as a bacterial topoisomerase I poison inhibitor [67]. Anziaic
acid is not active against E. coli with wild-type membrane permeability, but can inhibit
growth of gram-positive Bacillus subtilis with MIC of 6 μg/ml (14 μM). The 0.9 μM
concentration required to observe increase in DNA cleavage product formed by E. coli
topoisomerase I is significantly lower than the IC50 value of 19 μM for inhibition of the
relaxation activity as expected for topoisomerase poison inhibitor. Anziaic acid can inhibit
type IIA topoisomerase activities (E. coli DNA gyrase and human topoisomerase IIα) with
similar IC50 values, but inhibition against type IB human topoisomerase I is much weaker.
Anziaic acid could potentially interfere with enzyme–divalent ion interactions at the active
site [67]. The poison inhibitor effect of anziaic acid on human topoisomerase IIα might
partly account for its cytotoxicity against human pulmonary artery endothelial cells (CC50 =
21 μM). Total synthesis of anziaic acid and its analogues was carried out subsequently for
preliminary structure–activity analysis of topoisomerase Inhibition and antibacterial activity
[78]. The results showed that the dimeric scaffold and the free carboxylate of the compound
are essential for topoisomerase Inhibition. The negatively charged carboxylate may be
required for divalent ion interaction in the topoisomerase active site but antibacterial assays
showed that the carboxylate is not required for antibacterial activity, suggesting that there is
Future Med Chem. Author manuscript; available in PMC 2016 January 01.
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an unknown antibacterial mode of action in addition to topoisomerase Inhibition. The
lipophilic n-pentyl alkyl substituents augment both topoisomerase inhibition and
antibacterial activity [78].

Author Manuscript

Dual inhibition of both type IIA bacterial DNA topoisomerases, gyrase, and topoisomerase
IV has been utilized to reduce the emergence of drug-resistant bacterial pathogens [12,79].
For bacterial pathogens with only one type IIA topoisomerase, such as M. tuberculosis, dual
inhibition of both type IA topoisomerase I and type IIA DNA gyrase could provide the same
advantage of potentially reducing drug resistance frequency. Type IA and type IIA
topoisomerases share many mechanistic and structural similarities, including the formation
of a 5′-phosphotyrosine covalent linkage by active site tyrosine in CAP-like domains and
requirement of divalent ions bound by TOPRIM domains [80,81]. In addition to anziaic
acid, 2,4-diiodoemodin (Compound 9 in Figure 4), a haloemodin derived from the bioactive
natural product emodin also exhibits dual inhibition against DNA gyrase and bacterial
topoisomerase I [74]. Complete inhibition of these bacterial topoisomerase activities can be
achieved with concentrations of 30–90 μM, while human topoisomerase I and IIα were not
inhibited. The MIC of 2,4-diiodoemodin against S. aureus (2 μg/ml) is comparable to
vancomycin, with strong activities against other Gram-positive bacteria, including drugresistant isolates, also observed [74]. S. aureus-induced keratitis can be cured in rabbit
model, demonstrating the therapeutic efficacy of this compound. The antibacterial spectrum
can be expended into Gram-negative bacteria if penetration through the bacterial outer
membrane is assisted by polymyxin B nonapeptide [74].

Author Manuscript

The known type IIA human topoisomerase II poison inhibitor, m-AMSA was reported to
inhibit the relaxation activity of M. tuberculosis and M. smegmatis topoisomerase I in follow
up of virtual screening on a homology model of M. tuberculosis topoisomerase I [82]. DNA
cleavage was stimulated up to 1.7 fold, and m-AMSA can inhibit the growth of these
mycobacteria. However, at least part of the growth inhibition may be due to DNA
intercalation and inhibition of other DNA enzymes. In previous screening using the triplex
formation based assay, m-AMSA and related compounds were also identified as inhibitors
of the relaxation activity type IIB Methanosarcina mazei topoisomerase VI [83]. Utilization
of this class of acridine-based compounds as specific type IA topoisomerase Inhibitors
would require greater selectivity. The same caution of target selectivity also applies to the
alkaloid ungeremine found to inhibit mammalian as well as bacterial type I and type II
topoisomerases [84], and the other polyphenolic compounds discussed earlier in this review,
as such compounds are frequent hits in many biochemical assays.
Protein inhibitors of bacterial topoisomerase I
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In addition to small molecules, certain proteins have also been shown to inhibit the
relaxation activity of bacterial topoisomerase I. These include the E. coli Tn5 transposase
discussed in the previous review [19] and M. tuberculosis MazF homolog Rv1495 [85].
Rv1495 can inhibit the DNA cleavage activity of M. tuberculosis topoisomerase I. The
negative interplay of the direct physical interaction between the two proteins also resulted in
the inhibition of the mRNA cleavage activity of Rv1495 by the C-terminal domain of M.
tuberculosis topoisomerase I. Overexpression of Rv1495 or its N-terminal fragment in M.
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smegmatis can inhibit cell growth [85]. This result is significant for the potential modulation
of bacterial topoisomerase I activity and by toxin–antitoxin system in relationship to
dormancy regulation. Interaction between bacterial topoisomerase I and toxin protein may
possibly be found also in other bacteria, including E. coli [11]. It is plausible that small
molecules could be effective antibiotics by mimicking the action of protein inhibitors of
bacterial topoisomerase I. Monoclonal antibodies that can inhibit the relaxation activity of
M. tuberculosis and M. smegmatis topoisomerase I have been described [86,87]. These
antibodies can act with different mechanisms, including stimulation of DNA cleavage [86]
as well as enhancing the closing of the DNA gate after DNA cleavage [87]. These antibodies
could be valuable for the design of novel bacterial topoisomeraseI inhibitors.

Conclusion & future perspective
Author Manuscript
Author Manuscript

The true validation of bacterial topoisomerase I as a druggable target for antibiotics
discovery would require the identification of an antibacterial compound that involves
topoisomerase I in its major mode of action. The effect of topoisomerase I expression level
on antibacterial potency can provide some quick indication of whether topoisomerase I may
be one of the cellular targets for growth inhibition. Overexpression of topoisomerase I
should have protective effect against catalytic inhibitors as demonstrated for seconeolitsine
[69], but should conversely sensitize the bacteria to the action of a poison inhibitor, as
suggested for DMA [70]. It should be cautioned that the role of the relaxation activity of
topoisomerase I in regulation of global DNA supercoiling and transcription elongation
during stress response may be significant for degree of sensitivity to DNA intercalators or
other stress-inducing agents. To demonstrate convincingly that the antibacterial mode of
action requires direct interactions between the compound and cellular topoisomerase I, it is
still very much desirable to isolate resistant mutants with mutations in the topA gene, and
then to show that the compound MIC can be affected when the identified topA mutation is
introduced into the original drug sensitive genetic background. This has not been carried out
for any bacterial topoisomerase I inhibitors.

Author Manuscript

Testing of selectivity of bacterial topoisomerase I inhibitors against human topoisomerases
has so far only involved type IB and type IIA human topoisomerases. However, there are
two type IA topoisomerases in human, TOP3α and TOP3β, that should be evaluated in any
future development of bacterial topoisomerase Inhibitors into drug leads. There are many
examples of US FDA-approved drugs that target either bacterial type IIA topoisomerases as
antibiotics or human type IIA topoisomerases as anticancer drugs, so it should be possible to
optimize the structures of type IA topoisomerase Inhibitors for selectivity against either
bacterial or human type IA topoisomerases. Mammalian TOP3α is essential for embryonic
development, and its DNA decatenation activity plays an important role in genomic stability
[88]. Human TOP3β has RNA topoisomerase activity that affects neurodevelopment and has
been associated with mental disorders [49,50]. Selective small molecule inhibitors for these
human type IA topoisomerase activities could be very useful research tools for experimental
investigations with implications for human diseases.
Attempts have been made to model the interactions between the newly discovered bacterial
topoisomerase I inhibitors with the target enzyme [69,73,82] to support the proposals of
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possible mechanisms of action or to carry out virtual screening. Structure-based drug design
and identification of druggable sites on the enzyme would benefit greatly from an
experimentally determined structure of the topoisomerase–inhibitor or topoisomerase–
DNA–inhibitor complex. To limit potential mutagenicity or cytotoxicity, it would be
advantageous to occupy the drug-binding sites with molecular scaffolds that are not strong
DNA binders. Structural models of S. pneumoniae and M. tuberculosis topoisomerase I have
been built based on homology with available topoisomerase I structures [69,82]. Additional
three-dimensional structures of topoisomerase I enzymes of the targeted pathogens would
improve the potential accuracy of in silico results. While it is expected that the DNA
cleavage–religation equilibrium of type IA topoisomerases is primarily controlled by the Nterminal toroid like domain, the C-terminal domain is also required for the overall relaxation
activity [89,90], and may affect the cleavage–religation equilibrium through indirect
allosteric effects [20]. Elucidation of the C-terminal domain structures should further aid the
drug discovery effect targeting bacterial topoisomerase I.
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Executive summary
Type IA topoisomerase as a novel bactericidal target
•

Bacterial topoisomerase I is a high value target for antibacterial drug discovery
that remains to be fully utilized.

•

Antibiotics acting as bacterial topoisomerase I poison inhibitors have the
potential to be effective against a broad spectrum of bacterial pathogens due to
the presence of topoisomerase I in every bacterium.

Assays development for high-throughput screening

Author Manuscript

•

High-throughput screening assays are available to identification of inhibitors of
bacterial topoisomerase I overall catalytic cycle for relaxation of negative
supercoils, as well as the specific step of DNA rejoining.

•

It remains to be seen if these high-throughput screening assays can provide
selective hits with topoisomerase I inhibition as mode of action for antibacterial
efficacy.

New bacterial topoisomerase I inhibitors

Author Manuscript

•

Certain bacterial topoisomerase I inhibitors derived from phenanthrenes and
bisbenzimidazoles have been shown to be selective inhibitors of bacterial
topoisomerase I with minimal effect on human topoisomerases and limited
cytotoxicity.

•

There is some evidence from effect of recombinant bacterial topoisomerase I
overexpression that bacterial topoisomerase I inhibition is involved in their
modes of action.

Natural products inhibitors
•

Natural products represent a valuable source of molecular diversity that should
be further exploited for future identification of bacterial topoisomerase I
inhibitors.

•

There is a potential for identification of dual inhibitors of bacterial type IA and
type IIA topoisomerases.

Future perspective

Author Manuscript

•

Potency and selectivity of newly identified bacterial topoisomerase I inhibitors
(summarized in Table 1) may suggest promising approaches for future research.

•

Antibacterial mode of action of bacterial topoisomerase I inhibitors need to be
confirmed by characterization of resistant mutants.

•

Study of structure–activity relationship and structure-based drug design would
benefit from structures of topoisomerase–inhibitor or topoisomerase–DNA–
inhibitor complexes.
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There is a great need for identification of druggable sites in the enzyme structure
which can be exploited by molecular scaffolds that are not strong DNA binders.
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Figure 1.
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Principle of fluorescence-based assay for identification of bacterial topoisomerase I poison
inhibitors that can increase the level of DNA cleavage products reported as fluorescence
signal increase.
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Figure 2.

Alkaloid phenanthrenes active for inhibition of Streptococcus pneumoniae topoisomerase I
relaxation and cell growth.
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Figure 3.

Comparisons of Hoechst 33258, Hoechst 33342 with bisbenzimidazole analogues selective
for bacterial topoisomerase I inhibition:DMA [70], DPA 153 [72], 12b [73].
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Natural product derived compounds that can act as dual inhibitors of bacterial topoisomerase
I and DNA gyrase.
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